Dear Editor,

While previous findings indicate that blockade of the chemokine receptor CCR3 can be viewed as an attractive therapeutic alternative to actual treatments in inflammatory bowel diseases (IBD), we demonstrate herein that CCR3 deficiency or pharmacological blockade does not protect and even aggravates clinically, histologically, and biologically DSS-induced colitis. Interestingly, we show that a subpopulation of colonic regulatory T (Treg) cells express CCR3 providing an explanation for this unexpected deleterious effect of CCR3 inhibition or absence during experimental colitis.

Over the past two decades, several drugs (eg, biologics and tofacitinib) have changed IBD management. However, a significant proportion of patients remain or became refractory to these drugs, indicating an urgent need for new therapeutic targets.

CCR3 is a chemokine receptor, highly expressed by eosinophils and basophils, that have been implicated in autoimmune disorders and allergic diseases. CCR3 binds a wide range of ligands necessary for chemotaxis and tissue infiltration, including RANTES (CCL5), MCP-3 (CCL7), MCP-4 (CCL13), MIP-5 (CCL15), CCL18 (MIP-4), Eotaxin 1 (CCL11), Eotaxin-2 (CCL24), Eotaxin-3 (CCL26), and MEC (CCL28). Among these, eotaxin-1 is a key regulator of intestinal inflammation as demonstrated experimentally and clinically. Similarly, eotaxin-2, is also increased in ulcerative colitis (UC) patients.

All these lines of evidence provide a basis for targeting the eosinophil/eotaxin axis in patients with UC. In this prospect, Bertilimumab, an IgG4 monoclonal antibody that targets eotaxin-1, with a very high affinity and specificity, was developed and is currently in phase 2 clinical trial for the treatment of moderate to severe UC (NCT01671956). In addition, anti-eotaxin-2 antibodies are currently investigated for their potential use in the treatment of IBD (US Patent # 9,067,989).

Experimental and clinical data indicate that RANTES is also a player of IBD. Moreover, clinical investigations showed an over-expression of eotaxin-3 and MIP-2 in the tissue and serum of UC patients.

Therefore, to explore the relevance of CCR3 inhibition in colitis, we first decided to block CCR3 using GW766994, a CCR3 selective antagonist, during DSS-induced colitis in mice (Figure 1A). Surprisingly, GW766994 treatment was associated with a higher incidence rate (Figure 1B) and a more severe disease as assessed by DAI (disease activity index), body-weight loss and survival rate (Figure 1C-E) compared to DSS control mice.

Moreover, colon length reduction or fecal lipocalin levels, two markers of gut inflammation remained unaffected by CCR3 antagonist treatment (Figure 1F and G). Colonos of GW766994-treated mice showed similar histological damages (crypts, architecture loss, and leukocytes infiltration) to non-treated DSS mice (Figure 1H, 1I).

To challenge the results obtained with a pharmacological approach, we used a genetic CCR3 deficiency model. DSS was therefore induced in WT and CCR3 KO BALB/c mice (Figure 2A). Disease incidence (Figure 2B) and severity (Figure 2C) was significantly higher in CCR3-deficient mice than in WT mice following DSS administration. Such disease worsening was also reflected by a higher body-weight loss and a trend to a lower survival rate (Figure 2D,E) in CCR3 KO mice compared to WT mice. Moreover, shortening of the colon and increase of fecal lipocalin-2 level confirmed these findings (Figure 2F,G). Finally, histological examination of CCR3 KO mice showed slightly higher tissue damages in response to DSS, as observed for GW766994-treated mice (Figure 2H,I). Taken together, these results show that CCR3 KO mice are prone to develop a more severe DSS colitis, suggesting a protective role for CCR3 during colitis.

T-helper lymphocytes expressing IL-17 (Th17) and regulatory T cells (Treg) are critical regulators of intestinal inflammation. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
barrier function and key players in colitis. To investigate the contribution of CCR3 to DSS colitis susceptibility, we performed flow cytometric analysis of Th17/Treg population in colon and mesenteric lymph nodes (mLN). No difference in frequency or absolute number of Th17 relative to CCR3 deficiency or blockade was found (Figure S1), suggesting that DSS polarizes Th17 response independently of CCR3.

Interestingly, while in basal conditions, both WT and CCR3-deficient mice (left panels) had the same frequency (Figure 3B) and absolute cell number (Figure 3C) of Tregs, abundance of Treg cells was higher in colonic lamina propria from WT mice than in CCR3 KO mice (Figure 3C, left panel) after DSS-challenge. Similar results, were obtained for GW766994-treated animals in comparison to DSS-nontreated control mice (Figure 3B,C, right panels). In mLN, frequency and absolute number of CD3+ CD4+ FoxP3+ Treg cells were significantly decreased in CCR3 KO mice and GW766994-treated mice (Figure 3D,E, right panels) compared to WT control mice. Consequently, a decrease of Treg over Th17 cells ratios was observed in CCR3 KO mice and GW766994-treated mice in comparison to control mice, particularly in mLN (Figure S2B). Our data show that CCR3 deficiency or blockade suppresses Treg response in the large intestine and mLN of mice, suggesting that CCR3 limits gastrointestinal
inflammation via the control of Treg cell abundance in these tissues.

As indicated in Figure 4A, Immgen database indicated that CCR3 is expressed by Treg FoxP3+ specifically amongst T cells. We thus analyzed CCR3 expression on Treg cells by flow cytometry. A shown in Figure 4, a fraction of colonic resident and mLN Treg cells (Figure 4B and 4C) express CCR3 at their cell surface under physiological conditions. Such CCR3 expression is consistent with the diminished level of Treg cells observed in colonic lamina propria and mLN of both CCR3-deficient and GW-766994-treated DSS mice. Since some lamina propria Treg cells express RORyt and differ in their function from “classical” Tregs, we investigated the consequence of CCR3 blockade/deletion on these colonic RORyt+ Treg. Our results indicate that most of the colonic CCR3 positive Tregs were classical RORyt+ Treg, and that CCR3 blockade or deletion did not affect the RORyt+ Treg population (Figure 4D and 4E).

Previous reports indicate that CCR3 receptor is also expressed by splenic and adipose tissue Treg cells. Taking altogether, our results support an immunomodulatory role of CCR3 in shaping the intestinal immune response through Treg cell population in intestinal tissues.

Although all strains were housed in the same animal facility and all precautions were taken to normalize the microbiota of the different strains, we cannot exclude that variation in microbiota composition between strains could have contributed to the phenotypes observed.

In conclusion, our findings do not support the development of CCR3 blockers as potential therapeutic targets for human IBD and shed a new light on Treg cells contribution to the pathogenesis of IBD.
Figure 3 Regulatory T cell (Treg) population is impaired by CCR3 inhibition in DSS-induced colitis. A, Flow cytometry dot plots showing Treg gating strategy. B, Frequency of CD3+ CD4+ FoxP3+ RORγt Treg cells isolated from colonic lamina propria of mice challenged or not with DSS. C, Treg cell count in colonic lamina propria of mice challenged or not with DSS. D, Frequency of CD3+ CD4+ FoxP3+ Treg cells isolated from mesenteric lymph nodes (mLNs) of mice challenged or not with DSS. E, Treg cell count in mLN of mice challenged or not with DSS. (n = 6-9/group). Data are expressed as mean ± SEM. ANOVA with Tukey posthoc test for multiple comparisons was used for statistical differences between groups. n.s: non-significant; *P < .05 and **P < .01.

Author Contribution
P.N., L.P.-B., J.-Y.J., and D.M. designed the study and supervised the project; J.H. and M.F. designed parts of the study and performed most of the experiments with the help of M.T. and F.S.; M.F. wrote the manuscript; D.M., J.-Y. J., L.P.-B., edited the manuscript.

Acknowledgments
We thank Glaxo Smith Kline for kindly providing GW766994. This work was supported by the Region Grand Est and by the Fondation Arthritis. M.F. was supported by a fellowship from french PIA project « Lorraine Université d’Excellence », ANR-15-IDEX-04-LUE. We thank Dr Huguette LOUIS from the Cytometry Core Facility of UMS2008/US40 IBSLor (Université de Lorraine, CNRS, INSERM), F-54000 Nancy, France. We thank Lauralie Christophe (IMoPA, Université de Lorraine) for animal care. The authors declare no competing financial interests.

Data Availability Statements
The data underlying this article are available in the article and in its online supplementary material.
FIGURE 4  Colonic regulatory T cells (Treg) express CCR3 receptor. A, Immune cell expression of CCR3 according to Immgen data base (www.immgen.org). B, Frequency of CD3+ CD4+ FoxP3+ RORγt Treg cells isolated from colonic lamina propria of healthy WT and CCR3 KO mice. Representative dot plots of CCR3 expression on colonic lamina propria Tregs isolated from healthy WT and CCR3 KO mice. CCR3 expression on colonic lamina propria Tregs isolated from healthy WT and CCR3 KO mice. C, Frequency of CD3+ CD4+ FoxP3+ Treg cells isolated from mesenteric lymph nodes (mLN)s of healthy WT and CCR3 KO mice. Representative dot plots of CCR3 expression on mLN Tregs isolated from healthy WT and CCR3 KO mice. D, Dot plot of RORγt and CCR3 staining in Foxp3 colonic Tregs. E, Frequency of RORγt+ Treg in lamina propria of mice challenged or not with DSS and treated with GW766994. Data are expressed as mean ± SEM. ANOVA with Tukey posthoc test for multiple comparisons was used for statistical differences between groups. n.s: non-significant; ***P < .001; and ****P < .001

Laurent Peyrin-Biroulet2,3
Jean-Yves Jouzeau1,4,*
David Moulin1,5,*

1 IMoPA, UMR7365 CNRS-Université de Lorraine, Vandœuvre Les Nancy, France
2 Université de Lorraine, CNRSIMoPA, Nancy, France
3 NGERE, UMR-U1256 INSERM-Université de Lorraine, Vandœuvre Les Nancy, France
4 Service de Pharmacologie Clinique et de Toxicologie, CHRU-Nancy, Nancy, France
5 CHRU de Nancy, Contrat d’interface, Vandœuvre Les Nancy, Nancy, France

Correspondence
David Moulin, IMoPA, UMR7365 CNRS-Université de Lorraine, Vandœuvre Les Nancy, France.
Email: david.moulin@univ-lorraine.fr

"These authors contributed equally to this work
*These authors contributed equally to this work

ORCID
David Moulin https://orcid.org/0000-0001-6619-5769

REFERENCES

1. Ahrens R, Waddell A, Seidu L, et al. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. *J Immunol*. 2008;181(10):7390-7399. https://doi.org/10.4049/jimmunol.181.10.7390.

2. Vieira AT, Fagundes CT, Alessandri AL, et al. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. *Am J Pathol*. 2009;175(6):2382-2391. https://doi.org/10.2353/ajpath.2009.090093.

3. Mir A, Minguez M, Tatay J, et al. Elevated serum eotaxin levels in patients with inflammatory bowel disease. *Am J Gastroenterol*. 2002;97(6):1452-1457. https://doi.org/10.1016/S0002-9270(02)04043-1.

4. Manousou P, Kolios G, Valatas V, et al. Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in vitro studies. *Clin Exp Immunol*. 2010;162(2):337-347. https://doi.org/10.1111/j.1365-2249.2010.04248.x.

5. Immune Pharmaceuticals A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis. clinicaltrials.gov; 2018.

6. Ansari N, Abdulla J, Zayyani N, Brahim U, Taha S, Satir AA. Comparison of RANTES expression in Crohn’s disease and ulcerative colitis: an aid in the differential diagnosis?. *J Clin Pathol*. 2006;59(10):1066-1072. https://doi.org/10.1136/jcp.2005.034983.

7. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AEI, Wallace JL. The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. *J Immunol*. 2001;166(1):552-558. https://doi.org/10.4049/jimmunol.166.1.552.

8. Takahashi K, Imaeda H, Fujimoto T, et al. Regulation of eotaxin-3/CC chemokine ligand 26 expression by T helper type 2 cytokines in human colonic myofibroblasts. *Clin Exp Immunol*. 2013;173(2):323-331.

9. Kotarsky K, Sitnik KM, Stenstad H, et al. A novel role for constitutively expressed epithelial-derived chemokines as antibacterial peptides in the intestinal mucosa. *Mucosal Immunol*. 2010;3(1):40-48. https://doi.org/10.1038/mi.2009.115.

10. Dioszeghy V, Mondoulet L, Puteaux E, et al. Differences in phenotype, homing properties and suppressive activities of regulatory T cells induced by epicutaneous, oral or sublingual immunotherapy in mice sensitized to peanut. *Cell Mol Immunol*. 2017;14(9):770-782. https://doi.org/10.1038/cmi.2016.14.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.